Vaxart’s Annual Meeting Postponed: Key Details for Stockholders
Vaxart, Inc. (NASDAQ: VXRT), a pioneering biotechnology organization, has announced an important update regarding its upcoming Annual Meeting of Stockholders. Originally set to occur on a previously scheduled date, the Annual Meeting has now been adjourned to June 2, 2025. This event will take place at 8:30 a.m. Pacific Time and will be conducted in a virtual-only format, allowing stockholders to participate easily from the comfort of their homes.
Voting Process for Stockholders
All stockholders who are on record as of March 26, 2025, and have not yet cast their votes are strongly encouraged to do so by June 1, 2025, before the cutoff of 11:59 p.m. Eastern Time. This meeting will focus on several proposals outlined in Vaxart's definitive proxy statement, which has already been submitted to the U.S. Securities and Exchange Commission for consideration. Stockholders who have previously submitted a proxy are advised that their votes will be counted during the adjourned meeting unless they decide to revoke it according to the procedures specified in the Proxy Statement.
Understanding the Importance of Proposal No. 2
One of the critical proposals on the agenda is Proposal No. 2 concerning a Reverse Stock Split. The Vaxart Board of Directors strongly believes that this proposal presents numerous advantages for stockholders. One significant reason mentioned is that it will help regain compliance with Nasdaq’s minimum bid price requirement, ensuring that Vaxart’s common stock remains listed on the exchange—a vital factor for any publicly traded company.
In addition to compliance, a higher stock price resulting from a reverse stock split could enhance the Company’s attractiveness to investors. Many brokerage firms often hesitate to recommend lower-priced securities, leading to potential missed opportunities not only for Vaxart but also creating a barrier for investors looking to get involved. Furthermore, analysts frequently avoid providing coverage for lower-priced stocks, resulting in reduced visibility within the investment community.
Preparing for the Virtual Meeting
Stockholders will be able to access the virtual meeting by visiting Vaxart's designated website and entering the 16-digit control number found in their proxy materials or notices. This platform reflects Vaxart's commitment to securing participation from its shareholders in a modern and accessible format, showing adaptability in an ever-evolving corporate environment.
As the adjournment progresses, Vaxart continues to actively solicit votes from its stockholders. Encouragement is given for stockholders to consider their voting options, especially for those who initially opposed Proposal No. 2, as they have the opportunity to revise their votes in support of this proposal.
Contact Information for Assistance
Vaxart understands that navigating these procedures can sometimes be confusing, which is why they have provided assistance through their proxy solicitation firm. Stockholders in need of help with the voting process can reach out to Campaign Management, LLC. Their team is available to address questions and provide support, ensuring that every voice is heard during this critical decision-making time.
About Vaxart
Vaxart is at the forefront of biotechnology innovation, focused on developing oral recombinant vaccines leveraging its distinctive delivery platform. Their approach is revolutionary, providing vaccines that can be administered in pill form and that do not require refrigeration, thus eliminating the risks associated with traditional needle-based administrations. Currently, Vaxart's projects include vaccines designed to combat various viruses like coronavirus, norovirus, and influenza, alongside a therapeutic vaccine aimed at human papillomavirus (HPV), marking Vaxart’s entrance into the immune-oncology space.
The company is dedicated to advancing its research and has filed numerous domestic and international patent applications to protect its novel oral vaccination technologies. As Vaxart continues to make significant strides in their development programs, they remain committed to bringing innovative solutions to the market that will transform how vaccines are delivered.
Frequently Asked Questions
1. What was announced regarding Vaxart’s Annual Meeting?
The Annual Meeting has been adjourned to June 2, 2025, at 8:30 a.m. Pacific Time.
2. How can stockholders participate in the virtual meeting?
Stockholders can access the meeting through a dedicated website by entering their 16-digit control number.
3. Why is Proposal No. 2 significant for Vaxart?
Proposal No. 2 is important as it involves a Reverse Stock Split, which can help the company meet Nasdaq listing requirements and increase investor interest.
4. Who can stockholders contact for assistance with voting?
Stockholders can contact Campaign Management, LLC for guidance with the voting process.
5. What technologies is Vaxart currently focusing on in its vaccine development?
Vaxart is developing oral vaccines for various viruses, including coronavirus, norovirus, influenza, and HPV.
